BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-283@pharmaconomics
DTSTAMP:20260707T050529Z
DTSTART;VALUE=DATE:20260521
DTEND;VALUE=DATE:20260522
SUMMARY:DNLI Phase 2 — BIIB122/DNL151
DESCRIPTION:Phase 2 trial results for BIIB122/DNL151 in Parkinson’s disease are due May 21\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000070/dnli-20260521.htm\n\nTrack it: https://www.pharmaconomics.com/e/283
URL:https://www.pharmaconomics.com/e/283
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DNLI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR